Aging and Frailty Study

Wake Forest University (WFU)

Status: Completed

Conditions: Aging; Frailty; Effects of Chemotherapy

Treatments: Other: Geriatric Assessments and Frailty Indices

Study type: Observational

Funder types: Other

Identifiers

NCT05268991

IRB00080711

WFBCCC 04721 (Other Identifier)

Details and patient eligibility

About

The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.

Full description

Primary Objective: Describe mean and variation of the electronic frailty index-cancer, geriatric measures, patient reported outcomes, and biomarkers of aging of chemotherapy, and their change.

Enrollment: 25 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 65 years and older
• Planned to initiate a new chemotherapy regimen
• Solid tumor malignancy of any stage or lymphoma
• Any performance status
• Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
• Life expectancy of ≥3 months

Exclusion criteria

• Initiating biologic, endocrine or immunotherapy only.
• Hematologic malignancy other than lymphoma.
• Concurrent radiation therapy.
• Planned inpatient chemotherapy.

Trial design

25 participants in 1 patient group

AGE Participants

Description:

Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting

Treatment:

Other: Geriatric Assessments and Frailty Indices